Thrombosis News and Research

Latest Thrombosis News and Research

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.

11 Dec 2009

Latest findings on how blood clots form can open door to the development of new drugs

The latest findings on how blood clots form could open the door to the development of new and better-targeted drugs for patients at risk of strokes or heart attacks.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

Experts call on Europe's policy makers to take urgent action against preventable strokes

A report launched today by experts from medical and patient communities calls on Europe's policy makers to take urgent action against preventable strokes that strike thousands of atrial fibrillation (AF) patients each year

9 Dec 2009

New guidelines on the management of antithrombotic agents for endoscopic procedures published

According to a new guideline from the American Society for Gastrointestinal Endoscopy (ASGE) regarding the management of antithrombotic agents for endoscopy, aspirin and/or NSAIDs may be continued for all elective endoscopic procedures.

9 Dec 2009

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Celgene International Sàrl announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma were presented during the American Society of Hematology’s annual meeting in New Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone prolonged time to progression, including complete responses, with manageable toxicity.

8 Dec 2009

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of REVLIMID plus low-dose dexamethasone (Rd) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

8 Dec 2009

Discovery presents a vital step towards efficient treatment of vascular injuries

Hyperglycemia starts a complex chain of events that damages blood vessels and cause cardiovascular disease. Scientists at Lund University Diabetes Centre (LUDC) have now been able to demonstrate why this happens, as well as how the destructive chain can be broken.

7 Dec 2009

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Boehringer Ingelheim today announced very positive results from their landmark RE-COVER™ study – the most advanced trial programme assessing a novel oral anticoagulant in development for acute venous thromboemolism (VTE) treatment – presented at the American Society of Hematology Annual Meeting1 and published in the New England Journal of Medicine online.

7 Dec 2009

New oral drug is safe and effective to combat clotting disorder

A new study provides welcome news for patients with a common clotting disorder known as venous thromboembolism (VTE).

7 Dec 2009

J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), announced today that results from the Phase III EINSTEIN-Extension (EXT) clinical trial of the novel oral anticoagulant rivaroxaban showed a significant reduction in the risk of recurrent symptomatic venous thromboembolism (VTE), compared to placebo, in patients who have been treated for a previous deep vein thrombosis (DVT) or pulmonary embolism (PE).

7 Dec 2009

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment.

7 Dec 2009

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).

7 Dec 2009

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

Alexion Pharmaceuticals, Inc. today announced presentation of data showing that the presence of Type II paroxysmal nocturnal hemoglobinuria (PNH) cells is correlated with thrombocytopenia, potentially indicating that patients with Type II cells experience ongoing platelet consumption and increased thrombosis risk.

7 Dec 2009

China life science companies receive 'Most Promising Company' awards

The 7th ChinaBio® Investor Forum, held December 2-3, 2009 in Tianjin, concluded a successful meeting by giving “Most Promising Company” awards to two young China life science companies.

7 Dec 2009

Dabigatran etexilate offers effective therapy to prevent recurrent VTE

Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.

6 Dec 2009

Application for regulatory approval of apixaban in Europe to be submitted

Bristol-Myers Squibb Company and Pfizer today announced that the companies are planning to submit an application for regulatory approval of apixaban in Europe for the prevention of venous thromboembolism (VTE) after orthopedic surgery in the first half of 2010.

4 Dec 2009

Risk of having a potentially fatal blood clot after surgery is higher, finds research

The risk of having a potentially fatal blood clot after surgery is higher and lasts for longer than had previously been thought, concludes new research published on bmj.com today.

4 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

Thrombosis News and Research

Latest Thrombosis News and Research

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Latest findings on how blood clots form can open door to the development of new drugs

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Experts call on Europe's policy makers to take urgent action against preventable strokes

New guidelines on the management of antithrombotic agents for endoscopic procedures published

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Discovery presents a vital step towards efficient treatment of vascular injuries

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

New oral drug is safe and effective to combat clotting disorder

J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

China life science companies receive 'Most Promising Company' awards

Dabigatran etexilate offers effective therapy to prevent recurrent VTE

Application for regulatory approval of apixaban in Europe to be submitted

Risk of having a potentially fatal blood clot after surgery is higher, finds research

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in